Moderna is a biotechnology company headquartered in Cambridge, Massachusetts, founded in 2010 around a single scientific premise: that mRNA could be used to instruct the body's own cells to produce proteins capable of treating or preventing disease. Since then, it has built one of the industry's most advanced mRNA technology platforms, which enables the design, research, and testing of multiple mRNA candidates within days. The company operates across 18 locations worldwide.
Its platform spans a broad range of therapeutic areas, including infectious diseases, immuno-oncology, rare diseases, cardiovascular conditions, and autoimmune diseases. Moderna currently has 45 development programs underway, supported by 36 ongoing clinical trials. Its approved products include SPIKEVAX and mNEXSPIKE, both COVID-19 vaccines, and mRESVIA, a vaccine for RSV.
Women make up a meaningful part of Moderna's workforce and leadership, reflecting broader trends in biotechnology where scientific and clinical roles attract strong female representation. The company's platform-centric model means that expertise in mRNA design, clinical development, and translational research sits at the core of its operations, alongside functions spanning regulatory affairs, manufacturing, and data science.
Moderna has set specific sustainability targets: net-zero carbon emissions for Scopes 1 and 2 by 2030, and for Scope 3 by 2045. Its stated mission is to deliver the greatest possible impact to people through mRNA medicines, with an emphasis on speed and scale in bringing new treatments to patients.